-
1 Comment
Bicycle Therapeutics plc is currently in a long term uptrend where the price is trading 23.3% above its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.2.
Bicycle Therapeutics plc's total revenue sank by 27.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 295.7% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 222.1% to $-17M since the same quarter in the previous year.
Based on the above factors, Bicycle Therapeutics plc gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US0887861088 |
Sector | Healthcare |
Industry | Biotechnology |
Beta | 1.47 |
---|---|
Target Price | 26.2727 |
Market Cap | 592M |
PE Ratio | None |
Dividend Yield | None |
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BCYC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025